PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPimozide
Pimozide
Pimozide (pimozide) is a small molecule pharmaceutical. Pimozide was first approved as Orap on 1984-07-31. It is used to treat huntington disease, psychotic disorders, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against D(2) dopamine receptor and 5-hydroxytryptamine receptor 2A. In addition, it is known to target D(3) dopamine receptor, voltage-dependent T-type calcium channel subunit alpha-1I, G protein-activated inward rectifier potassium channel 2, voltage-dependent T-type calcium channel subunit alpha-1G, potassium voltage-gated channel subfamily A member 10, 5-hydroxytryptamine receptor 1A, histamine H1 receptor, 5-hydroxytryptamine receptor 7, voltage-dependent T-type calcium channel subunit alpha-1H, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
mental disordersD001523
Trade Name
FDA
EMA
Pimozide (discontinued: Orap)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pimozide
Tradename
Company
Number
Date
Products
ORAPTevaN-017473 DISCN1984-07-31
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
orapazunapproved drug other2025-02-11
orapredNew Drug Application2024-12-05
pimozideANDA2017-11-25
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N05: Psycholeptics
N05A: Antipsychotics
N05AG: Diphenylbutylpiperidine derivatives, antipsychotics
N05AG02: Pimozide
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F2011327
Psychotic disordersD011618F20.8111215
Schizophrenia spectrum and other psychotic disordersD01996711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mental disordersD001523EFO_0000677F91.9112
DementiaD003704EFO_0003862F0311
Psychophysiologic disordersD011602F45.911
DepressionD003863F33.911
Anxiety disordersD001008EFO_0006788F41.111
Somatoform disordersD013001F4511
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.2122
Motor neuron diseaseD016472EFO_0003782G12.222
SclerosisD01259822
Intellectual disabilityD008607EFO_0003847F7311
Tourette syndromeD005879EFO_0004895F95.211
SyndromeD01357711
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Long qt syndromeD008133HP_0001657I45.8111
PharmacokineticsD01059911
Pharmacological phenomenaD00006943711
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.711
Drug interactionsD00434711
Type 2 diabetes mellitusD003924EFO_0001360E1111
EmergenciesD00463011
Bipolar disorderD001714EFO_0000289F30.911
TinnitusD014012H93.111
Post-acute covid-19 syndromeD00009402411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePimozide
INNpimozide
Description
Pimozide is a member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. It has a role as a H1-receptor antagonist, a serotonergic antagonist, a first generation antipsychotic, an antidyskinesia agent and a dopaminergic antagonist. It is a member of benzimidazoles, an organofluorine compound and a heteroarylpiperidine.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
Identifiers
PDB
CAS-ID2062-78-4
RxCUI
ChEMBL IDCHEMBL1423
ChEBI ID8212
PubChem CID16362
DrugBankDB01100
UNII ID1HIZ4DL86F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CACNA1I
CACNA1I
CACNA1H
CACNA1H
Organism
Homo sapiens
Gene name
CACNA1I
Gene synonyms
KIAA1120
NCBI Gene ID
Protein name
voltage-dependent T-type calcium channel subunit alpha-1I
Protein synonyms
Ca(v)3.3, calcium channel, voltage-dependent, alpha 1I subunit, calcium channel, voltage-dependent, T type, alpha 1I subunit, Voltage-gated calcium channel subunit alpha Cav3.3
Uniprot ID
Mouse ortholog
Cacna1i (239556)
voltage-dependent T-type calcium channel subunit alpha-1I (E9Q7P2)
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Pimozide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,851 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,467 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use